Delaware Chapter of the American College of CardiologyOur purpose is to contribute to the prevention of cardiovascular diseases, to ensure optimal quality of care for individuals with such diseases, and to foster the highest professional ethical standards. Please let us know what information you want to see here. Feel free to contact us with your ideas, needs and comments. |
ACC Live Courses For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings |
Latest in Cardiology from ACC.org
- New-Onset RBBB Post TAVR Associated With High Risk of PPIPatients developing right bundle branch block (RBBB) following TAVR is rare; however, patients that experience the complication may have a high risk of worsening electrical conduction requiring permanent pacemaker implantation (PPI) within the first week post procedure...
- ACC CardiaCast: Innovation in Action: Addressing Unmet Needs in Thrombotic ConditionsIn this episode, ACC Chief Innovation Officer Dr. Ami Bhatt is joined by ACC Vice President Dr. Roxana Mehran and Dr. Carolyn Lam to discuss thrombotic conditions and the importance of addressing gaps in treatment.
- Highlights From the Summer BOT RetreatEach year, the Board of Trustees (BOT) gathers for a three-day retreat to reflect on progress toward achieving the College's Mission and strategic goals. The retreat also provides dedicated time for longer-term planning and thoughtful discussion of opportunities, challenges and potential course corrections to ensure the College remains on track.
- New ACC/AHA Guideline Addresses Prevention, Detection, Evaluation and Management of High Blood PressureThe latest Clinical Practice Guideline from the ACC and the American Heart Association (AHA) and 11 other societies provides updated recommendations for clinicians on the prevention, detection, evaluation and management of high blood pressure in adults.
- AGENT IDE: Paclitaxel-Coated Balloon in Patients With Multilayer ISRTreating patients with multilayer in-stent restenosis (ISR) with a paclitaxel-coated balloon was associated with reduced risk of target lesion failure (TLF) at one year vs. an uncoated balloon, according to a subgroup analysis of the AGENT IDE trial published Aug. 11 in JACC.